Immunization with a tumor-cell-lysate-loaded autologous-antigen- presenting-cell-based vaccine in melanoma

Cancer Immunology Immunotherapy

Volumn 47, Issue 1, 1998, Pages 58-64

  Chakraborty, Nitya G ^a   Sporn, Jonathan R ^a   Tortora, Anne F ^a   Kurtzman, Scott H ^a   Yamase, Harold ^a   Ergin, M T ^a   Mukherji, Bijay ^a  

^a UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

Author keywords

Active immunotherapy; Cancer vaccine

Indexed keywords

CANCER VACCINE;

ANTIBODY PRODUCING CELL; ANTIGEN PRESENTING CELL; ARTICLE; AUTOIMMUNITY; CANCER CONTROL; CLINICAL ARTICLE; CORONARY ARTERY DISEASE; DELAYED HYPERSENSITIVITY; HUMAN; IMMUNIZATION; INFANT; MELANOMA; PHENOTYPE; PRESCHOOL CHILD; PRIORITY JOURNAL; SKIN CANCER; SUPPRESSOR CELL; TUMOR CELL CULTURE;

ANTIBODY FORMATION; ANTIGEN-PRESENTING CELLS; CANCER VACCINES; FEMALE; HUMANS; IMMUNOTHERAPY, ACTIVE; MALE; MELANOMA; VACCINATION;

EID: 0031684670     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002620050504     Document Type: Article

References (19)

1. Boon T, Bruggen P van der (1996) Human tumor antigens recognized by T lymphocytes. J Exp Med 183:725-729
2. Bruggen P van der, Bastin J, Gajewski T, Coulie PG, Boel P, De Smet C, Traversari C, Townsend A, Boon T (1994) A peptide encoded by human gene MAGE-3 and presented by HLA-A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE-3. Eur J Immunol 24:3038-3043
3. Brossart P, Bevan MJ (1997) Presentation of exogenous protein antigens on major histocompatibility complex class I molecules by dendritic cells: pathway of presentation and regulation by cytokines. Blood 90:1594-1599
4. Celluzzi CM, Mayordomo JL, Storkus WJ, Lotze MT, Falo LD Jr (1996) Peptide pulsed dendritic cells induce antigen specific CTL mediated protective tumor immunity. J Exp Med 183:283-286
5. Chakraborty NG, Tortora AF, Sporn JR, Kurtzman SH, Yamase H, Ergin MT, Mukherji B (1997) Melanoma cell lysate loaded autologous antigen presenting cell (APC) as a vaccine in melanoma. Proc Am Assoc Cancer Res Annu Meet 38:400
6. Espevic T, Nissen-Meyer J (1986) A highly sensitive cell line, WEHI 164 clone 13, for measuring factor/tumor necrosis factor from human monocytes. J Immunol Methods 95:99-103
7. Hu X, Chakraborty NG, Sporn JR, Kurtzman SH, Yamase H, Ergin MT, Mukherji B (1996) Enhancement of cytolytic T lymphocyte precursor frequency following immunization with the MAGE-1 peptide loaded antigen presenting cell based vaccine. Cancer Res 56:2479-2482
8. Jaeger E, Bernhard H, Romero P, Ringhoffer M, Arand M, Karbach J, Ilsenmann C, Hagedorn M, Knuth A (1996) Generation of cytotoxic T-cell responses with synthetic melanoma-associated peptides in vivo. Implications for tumor vaccines with melanoma-associated antigens. Int J Cancer 66:162-169
9. Marchand M, Weynants P, Rankin E, Arienti F, Belli F, Parmiani G, Cascinelli N, Bourlond A, Vanwijck R, Humblet Y, Canon JL, Laurent C, Naeyaert JM, Plagne R, Deraemaeker R, Knuth A, Jager E, Brasseur F, Herman J, Coulie, PG, Boon T (1995) Tumor regression responses in melenoma patients treated with a peptide encoded by gene MAGE-3. Int J Cancer 63:883-885
10. Mukherji B, Chakraborty NG, Yamasaki S, Okino T, Yamase H, Sporn JR, Kurtzman SH, Ergin MT, Ozols J, Meehan J, Mauri F (1995) Induction of antigen specific cytolytic T cells in situ in human melanoma by immunization with synthetic peptide-pulsed autologous antigen presenting cells. Proc Natl Acad Sci USA 92:8078-8082
11. Mukherji B, Guha A, Chakraborty NG, Sivanandham M, Nashed A, Sporn JR, Ergin MT (1989) Clonal analysis of cytotoxic and regulatory T cell response in human melanoma. J Exp Med 169:1961-1976
12. Nestle FO, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer S, Burg G, Schadendorf D (1998) Vaccination of melanoma patients with peptide- or tumor lysate- pulsed dendritic cells. Nat Med 4:328-332
13. Ohasi PS, Oehen K, Burki HP, Pircher T, Ohasi B, Odermatt B, Malissen B, Zinkernagel R, Hengartner H (1991) Ablation of "tolerance" and induction of diabetes by virus infection in virus antigen transgenic mice. Cell 65:305-317
14. Oldstone MBA, Nerenberg M, Sourthern P, Proce J, Lewicki H (1991) Virus infection triggers insulin-independent diabetes mellitus in transgenic model: role of anti-self (virus) immune response. Cell 65:319-332
15. Paglia P, Chiodini C, Rodolfo M, Colombo MP (1996) Murine dendritic cells loaded with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo. J Exp Med 183:317-322
16. Rosenberg SA, Yang JC, Schwartzentruber DJ, Hwu P, Marincola FM, Topalian SL, Restifo NP, Dudley ME, Schwarz SL, Spiess PJ, Wunderlic JR, Parkhurst MR, Kawakami Y, Seipp CA, Einhorn JH, White WE (1998) Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 4:321-327
17. Salgaller ML, Marincola FM, Cormier JN, Rosenberg SA (1996) Immunization against epitopes in the human melanoma antigen gp100 following patient immunization with synthetic peptides. Cancer Res, 56:4749-4757
18. Young L, Inaba K (1996) Dendritic cells as adjuvants for class I major histocompatibility complex-restricted antitumor immunity. J Exp Med 183:7-11
19. Zitvogel L, Mayordomo JL, Tjandrawn T, DeLeo AB, Clarke MR, Lotze MT, Storkus WJ (1996) Therapy of murine tumors with tumor peptide-pulsed dendritic cells; dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokine. J Exp Med 183:87-97